• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Bausch + Lomb Corporation

    2/14/23 5:14:30 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email
    SC 13G 1 d459284dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.    )*

     

     

    Bausch + Lomb Corporation

    (Name of Issuer)

    Common Shares, No Par Value

    (Title of Class of Securities)

    071705107

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☑ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 071705107

     

      1.    

      Name of Reporting Person

     

      Bausch Health Companies Inc.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      British Columbia, Canada

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      310,449,643

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

      310,449,643

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      310,449,643

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      88.7% (1)

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    (1)

    Based on 350,000,749 common shares, no par value, of Bausch + Lomb Corporation issued and outstanding as of October 28, 2022, as reported in Bausch + Lomb Corporation’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022. The Reporting Person owns these shares indirectly, through two wholly-owned subsidiaries, 1261229 B.C. Ltd. and 1375209 B.C. Ltd., each of which is organized under the laws of British Columbia, Canada.

     

    2


    Item 1.

     

      (a)

    Name of Issuer

    Bausch + Lomb Corporation

     

      (b)

    Address of Issuer’s Principal Executive Offices

    520 Applewood Crescent

    Vaughan, Ontario, Canada L4K 4B4

     

    Item 2.

     

      (a)

    Name of Person Filing

    Bausch Health Companies Inc.

     

      (b)

    Address of Principal Business Office or, if none, Residence

    2150 St. Elzéar Blvd. West

    Laval, Québec, Canada H7L 4A8

     

      (c)

    Citizenship

    British Columbia, Canada

     

      (d)

    Title of Class of Securities

    Common Shares, No Par Value

     

      (e)

    CUSIP Number

    071705107


    Item 3.If

    this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned:

    See Item 9 of the cover page.

     

      (b)

    Percent of class:

    See Item 11 of the cover page.

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

    See Item 5 of the cover page.

     

      (ii)

    Shared power to vote or to direct the vote:

    See Item 6 of the cover page.

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    See Item 7 of the cover page.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    See Item 8 of the cover page.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.


    Item 10.

    Certification

    Not applicable.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2023

     

    BAUSCH HEALTH COMPANIES INC.

    By:

      /s/ Seana Carson

    Name:

      Seana Carson

    Title:

      Executive Vice President, General Counsel
    Get the next $BLCO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    10/15/2024$19.00 → $25.00In-line → Outperform
    Evercore ISI
    7/10/2024$19.00Outperform
    Raymond James
    5/6/2024$16.00 → $18.00Equal-Weight → Overweight
    Morgan Stanley
    1/4/2024$19.00 → $17.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch + Lomb Announces Board Changes

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the Amended and Restated Director Appointment and Nomination Agreement, dated as of June 21, 2022, by and among the company and Mr. Carl C. Icahn and certain of his affiliates, terminated pursuant to its terms when the Icahn group's net long position in the common shares of Bausch + Lomb's parent company, Bausch Health Companies Inc., fell below the required threshold. In connection with the termination, Brett M. Icahn and Gary Hu have resigned from the Bausch + Lomb Board of Directors. "I appreciate Brett and Gary's valuable contributi

    8/18/25 5:01:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb to Participate in Upcoming Investor Conferences

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that members of its management team will participate in two investor conferences in September: J.P. Morgan European Leveraged Finance Conference September 3, 2025, London, U.K. Morgan Stanley Global Healthcare Conference September 8, 2025, 7:45 a.m. ET, New York, NY Executive Vice President and Chief Financial Officer Sam Eldessouky will participate in investor meetings at the J.P. Morgan conference. Chairman of the Board and Chief Executive Officer Brent Saunders and Sam Eldessouky will participate in a fireside chat at the Morgan S

    8/14/25 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Second-Quarter 2025 Results

    Revenue of $1.278 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $62 Million Adjusted EBITDA (non-GAAP)1 of $191 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $192 Million Revenue Grew 5% as Reported and 3% on a Constant Currency1 Basis Compared to the Second Quarter of 2024, which Absorbs the enVista® Intraocular Lenses Voluntary Recall Raising Full-Year 2025 Guidance to Reflect Solid Business Performance and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2025 financial results. "Our con

    7/30/25 6:57:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Saunders Brent L bought $248,072 worth of shares (22,000 units at $11.28) and was granted 22,000 shares, increasing direct ownership by 6% to 741,156 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/27/25 8:16:24 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/6/25 4:30:10 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    8/7/24 5:29:48 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Bausch + Lomb with a new price target

    H.C. Wainwright reiterated coverage of Bausch + Lomb with a rating of Buy and set a new price target of $15.00 from $20.00 previously

    5/2/25 7:51:06 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Bausch + Lomb from Overweight to Equal Weight and set a new price target of $15.00 from $24.00 previously

    3/28/25 8:14:16 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb downgraded by Citigroup with a new price target

    Citigroup downgraded Bausch + Lomb from Buy to Neutral and set a new price target of $22.00 from $24.00 previously

    12/11/24 7:25:38 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    SEC Filings

    View All

    Bausch + Lomb Corporation filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    8/18/25 5:06:46 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    SEC Form 10-Q filed by Bausch + Lomb Corporation

    10-Q - Bausch & Lomb Corp (0001860742) (Filer)

    7/30/25 5:17:52 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    7/30/25 7:00:37 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Controller and CAO Munsch Frederick was granted 7,529 shares, increasing direct ownership by 11% to 77,733 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    8/7/25 4:48:43 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    EVP and CFO Eldessouky Sam was granted 42,517 shares, increasing direct ownership by 15% to 320,816 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    8/7/25 4:46:53 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    President, Surgical Bonnefoy Luc was granted 6,146 shares, increasing direct ownership by 9% to 77,362 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    8/7/25 4:42:26 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For   Against   Broker Non-Votes Nathalie Bernier   337,617,248   1,924,336   8,383,437 Gary Hu   337,591,706   1,949,878   8,383,437 Brett Icahn   337,474,287   2,067,297   8,383,437 Sarah B. Kavanagh   337,602,211   1,939,373  

    5/21/25 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

    Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

    2/28/24 8:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

    Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

    2/21/24 7:00:00 AM ET
    $BLCO
    $EBS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BLCO
    Financials

    Live finance-specific insights

    View All

    Bausch + Lomb Announces Second-Quarter 2025 Results

    Revenue of $1.278 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $62 Million Adjusted EBITDA (non-GAAP)1 of $191 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $192 Million Revenue Grew 5% as Reported and 3% on a Constant Currency1 Basis Compared to the Second Quarter of 2024, which Absorbs the enVista® Intraocular Lenses Voluntary Recall Raising Full-Year 2025 Guidance to Reflect Solid Business Performance and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2025 financial results. "Our con

    7/30/25 6:57:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 30, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its innovative product pipeline. Additional details will follow closer to the event. Second-Qua

    6/30/25 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces First-Quarter 2025 Results

    Revenue of $1.137 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $212 Million Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $126 Million Revenue Grew 3% as Reported and 5% on a Constant Currency1 Basis Compared to the First Quarter of 2024 Updating Full-Year 2025 Guidance to Reflect Estimated One-Time Impact of enVista® Intraocular Lenses Voluntary Recall and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. "Our core business is performing well, and we remain focused on positioning

    4/30/25 6:57:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bausch + Lomb Corporation

    SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

    2/14/23 5:14:30 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care